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Rap lb is a 22-kDa  low molecular  mass  GTP-binding 
protein which is both a member of the Ras superfamily 
and a substrate for CAMP-dependent protein kinase. Re- 
cently, evidence has been presented to show that Rap lb  
is incorporated into  the detergent-extracted cytoskel- 
eton of platelets during thrombin-induced activation. 
The aims of this study were to compare the incorpora- 
tion of Rap lb into the detergent-extracted cytoskeleton 
after activation with different agonists,  to  examine the 
role of extracellular calcium  on the incorporation of Rap 
lb  into  the cytoskeleton, to investigate the relationship 
between the association of Rap lb  and other proteins 
with the cytoskeleton, and to determine the effect of 
phosphorylation of Rap lb  incorporation into  the cy- 
toskeleton. Platelets were activated with thrombin, 
A23187, phorbol myristate acetate, ADP, epinephrine, 
and collagen in  the presence and absence of calcium. 
The  time dependence of Rap lb  incorporation into  the 
detergent-extracted cytoskeleton was then measured. 
When platelets were activated by thrombin in the pres- 
ence of extracellular calcium, conditions which permit 
aggregation, incorporation of Rap lb  into the detergent- 
extracted cytoskeleton  was  biphasic.  Approximately 
20% of the  total cellular Rap lb  incorporated into the 
cytoskeleton within seconds and was followed by a 
slower  second phase of incorporation. In contrast, when 
platelets were activated by thrombin in  the absence of 
calcium, conditions which inhibit aggregation, or by the 
other agents in the presence or absence of calcium,  only 
the initial phase of Rap lb  incorporation into  the cy- 
toskeleton was  measured.  The incorporation of Rap lb  
paralleled the incorporation of membrane  glycoproteins 
(GP)  IIbLIIa nd PECAM-1, but not the incorporation of 
pp60""". The GTPase-activating protein for Ras (Ras- 
GAP) did not associate with the detergent-extracted cy- 
toskeleton. Two-dimensional isoelectric focusing SDS- 
polyacrylamide  gel electrophoresis of the total cellular 
and cytoskeletal Rap lb  showed that unphosphorylated 
as well as phosphorylated isoforms of Rap lb  were in- 
corporated into  the cytoskeleton in  the same  molar atio 
as was present in the  intact cell. Furthermore, the rates 
of incorporation of phosphorylated and unphosphoryl- 
ated Rap lb  into  the cytoskeleton  were  similar.  These 
experiments show that Rap lb  can regulate events that 
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take place within seconds after activation, such as the 
initial formation of the cytoskeleton, as well as longer 
term changes in  the cytoskeleton that occur in response 
to thrombin-induced aggregation. Furthermore, phos- 
phorylation could  modulate the (unknown) functions of 
Rap lb  as a component of the cytoskeleton. 
Blood platelets are inhibited  by  agents that increase  intra- 
cellular  levels of CAMP. This  inhibition has been  correlated  with 
the phosphorylation  by CAMP-dependent protein  kinase of mul- 
tiple  proteins,  including a 22-kDa  protein,  previously  termed 
p22  (1,2).  Phosphorylation of p22  occurred in intact  platelets  or 
in membrane  fractions  in  response to CAMP-dependent  protein 
kinase or its  catalytic subunit (3-10). Recently, we and  others 
(11-15) identified  p22 as a member of the  Ras  superfamily of low 
molecular  weight  G-proteins.'  Sequence  analysis  showed that 
the  22-kDa  protein  was  Rap l b  (15-18).' Phosphate  attachment 
occurred at a serine residue  (17,19)  on a carboxyl-terminal  site 
that was  identified as Arg-Lys-Lys-Ser(P,)-Ser-Cys (1&19). The 
carboxyl-terminal  cysteine  residue, 1 amino  acid  removed  from 
the phosphorylated  serine  residue,  is  modified  with a hydro- 
phobic  geranylgeranyl  moiety (20). Thus  the  site of phospho- 
rylation of Rap l b  is near the  site of membrane  attachment. 
Lapetina et al. (13)  have suggested that phosphorylation of Rap 
l b  may  regulate  membrane  localization. 
Recent  studies  have  shown that Rap l b  is  incorporated  into 
the  detergent-extracted  cytoskeleton3 of platelets  during  acti- 
vation  by  thrombin  (22). In contrast  to  other  cytoskeletal  pro- 
teins such as actin,  myosin,  and  actin-binding  protein  which 
incompletely  incorporate  into the cytoskeleton of platelets,  all 
of the immunodetectable Rap l b  was incorporated into the 
detergent-extracted cytoskeleton within 5 min  after  stimula- 
tion with thrombin. The purpose of this  study is to  further 
characterize the cytoskeletal  interactions of Rap  lb,  including 
the role of extracellular  calcium  in  Rap l b  incorporation  into 
the cytoskeleton. 
MATERIALS AND METHODS 
Reagents, buffers, and salts were  from Sigma. Collagen  was  from Or- 
ganon-Technika Company (Durham, NC). [32P10rthophosphate (1000 Ci/ 
The abbreviations used are: G-protein, GTP-binding protein; GAP, 
MES, 4-morpholineethanesulfonic acid; PAGE, polyacrylamide  gel  elec- 
GTPase-activating protein; PGI,, prostaglandin I,; GP, glycoprotein; 
trophoresis; IEF,  isoelectric  focusing; mAb,  monoclonal  antibody. 
Rap lb  has also been called smg-p21B (111, m22KG(I) (121, and 
thrombolamban (14). 
The activation-dependent cytoskeleton is a detergent-insoluble 
structure that forms  when platelets are activated by agonists such as 
thrombin. Absent in resting platelets, the cytoskeleton contains actin, 
myosin, actin-binding protein, and other contractile proteins. The acti- 
vation-dependent cytoskeleton is distinct from what has been termed 
the membrane skeleton (21) which is present in resting cells and is 
formed by actin, actin-binding protein, membrane glycoproteins  Ib, V, 
and E, and other proteins. 
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mol) and [3Hlserotonin (56 Ci/mol)  were purchased from DuPont NEN. 
M90, a murine monoclonal antibody against ~ 2 1 ~ ' ~ ~  (23), was a gift from 
Dr. Juan-Carlos Lacal (Bethesda, MD).  AP4, a murine monoclonal an- 
tibody to glycoprotein IIb, and mAb 327, a murine monoclonal antibody 
against pp60""", were  provided by Drs. T. Kunicki  (Milwaukee,  WI) and 
J. Brugge (Philadelphia, PA), respectively.  SEW-16, a polyclonal antisera 
to human PECA"1 was from Dr.  P. Newman  (Milwaukee,  WI).  RH-6, 
a polyclonal rabbit antibody against Ras-GAP, was prepared using a 
synthetic decapeptide corresponding to the Ras-GAP  carboxyl terminus. 
Human a-thrombin, obtained from Dr. Frank Church (Department of 
Pathology, University of North Carolina), was prepared as detailed else- 
where (24) and stored at  -80 "C in 750 nm NaCI,  20 nm MES, 3 mM NaN,, 
pH 7.5, until use. Platelet glycoprotein IIb was a gift from Dr. Leslie 
Parise (Department of Pharmacology, University of North Carolina- 
Chapel Hill) and was purified as outlined by Fitzgerald et  al. (25). Plate- 
let Rap l b  was purified as described  previously (17). 
Washed human platelets were prepared by differential centrifuga- 
tion from fresh human blood as described by White (26). Platelets were 
activated by performing a 1/100 dilution of activating agent into sus- 
pensions of stirred platelets at a concentration of lo9 cells/ml in citrated 
saline (20 nm citrate, 150 nm NaCI, pH 7.0). Final concentrations of 
activating agents were: thrombin, 1 uniuml; ADP,  1.0 mM; epinephrine, 
1.0 mM; phorbol 12-myristate 13-acetate, 10 p;A23187,3 PM; collagen, 
2 pg/ml. Controls were  also  performed with VlOO dilutions of carrier 
medium (citrated saline for thrombin, ADP, collagen, and epinephrine 
and Me,SO  for  phorbol 12-myristate 13-acetate and A23187).  For acti- 
vation with aggregation, 5 IMI CaC1, was  included in the citrated saline, 
whereas for activation without aggregation, 1.0 mM EDTA was  included 
in  the medium  before the addition of activation agents. In experiments 
where [3Hlserotonin release was measured, platelet-rich plasma was 
incubated for  30 min at 37 "C with 4 x 10"  Cum1 [3Hlserotonin prior to 
centrifugation. Cytoskeletons were extracted with a Triton X-100 lysis 
differential centrifugation procedure (27,281 as detailed elsewhere (22). 
In experiments where phosphoprotein profiles  were studied, plate- 
lets were loaded with [32Plorthophosphate and exposed to PGI, as fol- 
lows. The cells were suspended at a concentration of lo9 celldm1 in 
citrated saline with 0.1 pCi/ml [32Plorthophosphate and incubated 30 
min at 37 "C. PGI, or carrier buffer  (10 nm Tris base) was then diluted 
1AOO into the mixture for final prostaglandin concentrations of 1 and 0 
PM. The mixture was then incubated an additional 10 min at 37 "C. 
After the addition of 5 nm CaCl,, the platelets were activated with 1 
unit/ml thrombin and the cytoskeletons extracted. 
SDS-PAGE was  performed with the procedure of Laemmli (29) under 
reducing conditions  on  12.5%  polyacrylamide  gels. Molecularmass stand- 
ards were  soybean trypsin inhibitor (21 kDa), carbonic anhydrase (29 
kDa), ovalbumin (45 kDa), bovine serum albumin (67 m a ) ,  phospho- 
rylase b (97 kDa), and myosin (200 kDa). Two-dimensional IEF SDS- 
PAGE utilized the procedure of O'Farrell(30). Western blot analysis was 
performed by electrotransferring proteins to nitrocellulose and  then im- 
munodetecting using alkaline phosphatase-conjugated second antibody 
system. The amount of Rap l b  and glycoprotein IIb incorporated into the 
cytoskeleton was quantified in absolute terms by electrophoresing 3.0, 
1.0, 0.3, 0.1, 0.03, 0.01, and 0 pgAane quantities of purified material 
along with samples that contained unknown quantities of the proteins. 
Mer  color development, the nitrocellulose was densitometrically 
scanned and peak areas were used to quantify Rap l b  and GP IIb con- 
tents. PECAM-1 and pp60""" contents of the cytoskeletons were quan- 
tified in relative terms by electrophoresing 3-fold serial dilutions of the 
platelets; the undiluted platelet lane contained the same number of 
platelets as used to isolate the cytoskeletons in the cytoskeleton lanes. 
For Rap lb, glycoprotein IIb, PECA"1, Ras-GAP, and pp60'"" quan- 
titation, electrotransfers were immunodetected withM90,AP4, SEW-16, 
RH-6, and mAb 327, respectively. Total protein concentrations were 
measured with the method of Peterson (31). Autoradiography was per- 
formed by exposing  nitrocellulose to  X-ARB film after immunodetection. 
RESULTS AND DISCUSSION 
The amount of Rap l b  that was  incorporated  into  the  cytoskel- 
eton  when  platelets  were  exposed  to  different  activating  agents 
is  compared in Fig. 1. Platelets  were  activated  in the presence 
of calcium  for 5 min  with  each agent at the indicated  concen- 
trations, then cytoskeletons  were  isolated  by  extraction in 1% 
Triton X-100 and differential  centrifugation. The cytoskeletal 
fraction  was  subjected  to  SDS-PAGE  and Western blot  analysis 
to  quantify  Rap lb. Although all of the agents tested were  able 
to  induce the incorporation of Rap l b  into the cytoskeleton, 
with  the cytoskeleton. Washed platelets were activated in  the pres- 
FIG. 1. The effect of different  agonists on Rap l b  association 
ence of calcium with thrombin (IZa, 1 uniuml), phorbol 12-myristate 
13-acetate (PMA, 10 PM),  A23187 (A23, 3 p), collagen (Col, 2 pg/ml), 
ADP (1 mM), or epinephrine (Epi, 1 mM). Control platelets (Con) were 
treated with buffer. After 5 min, cytoskeletal structures were isolated by 
Triton  X-100, lysis, and differential centrifugation. The Rap l b  content 
of the cytoskeleton  was measured by Western blot analysis using M90 
as described under "Materials and Methods." The results for  each  ago- 
nist are expressed as nanomoles of Rap lb/mg of cytoskeleton protein. 
The percentage of total [3Hlserotonin released with each activating 
agent is given in parentheses. 
thrombin  was  nearly  five  times  more  effective than the other 
agonists.  Since the cytoskeleton  formed  after  stimulation with 
thrombin  was  also  more  extensive than with  the  other  agents, 
the results in Fig. 1 have  been  expressed as nanomoles of Rap 
lb/mg of cytoskeletal protein. If, instead, the results  are  ex- 
pressed as cytoskeletal  Rap l b  per  mg of platelet  protein,  the 
difference  between  thrombin  and the other  agonists is greatly 
increased  (not  shown).  Thus,  the  results in Fig. 1 indicate that 
even  when  normalized  for the differences in cytoskeleton for- 
mation  with the various  agonists,  Rap lb  was  more  completely 
incorporated into the cytoskeleton with thrombin than with 
other  agents. As expected,  thrombin  was  also  more ffective at 
stimulating  full  activation of platelets as measured  by  the re- 
lease of [3Hlserotonin  (Fig. 1, numbers  above  bars). 
Fig. 2 shows a time  course of Rap l b  association  with  the 
cytoskeleton in response  to  thrombin. I  the  presence of calcium, 
the rate of R a p   l b  incorporation  into the cytoskeleton  was ini- 
tially  rapid  and  was followed by a slower  second  phase  (Fig.  2, 
panel A, solid symbols).  Approximately 20% of the total  Rap l b  
was  associated  with the cytoskeleton at 30 s. Incorporation of 
Rap l b  was  typically  complete  by  10  min,  but  varied  somewhat 
from  donor  to donor. In the  absence of calcium,  incorporation of 
Rap l b  showed  only the single  initial  phase  (Fig.  2,panelA,  open 
symbols). In contrast  to  thrombin, the other  agonists,  phorbol 
12-myristate  13-acetate,  A23187,  collagen, ADP, and epineph- 
rine,  induced  only the initial  rapid  phase  ofincorporation f Rap 
l b  into the cytoskeleton  in  the  presence and in the  absence of 
calcium  (data  not  shown),  leading  to the association of 20% or 
less of the total  cellular  Rap l b  with  the  cytoskeleton. 
The  calcium-dependent  association of Rap l b  with the cy- 
toskeleton is similar  to  what has been  described  for  platelet 
membrane GP IIb-IIIa (27, 28, 32). To explore this parallel 
further,  Rap l b  incorporation  into  the  cytoskeleton  was com- 
pared  directly  with  GP  IIb-IIIa. As shown in Fig. 2 (panel B ) ,  
GP  IIb-IIIa  showed the same  biphasic  calcium-dependent as- 
sociation  with the cytoskeleton as Rap  lb.  While the associa- 
tion of Rap l b  and G P  IIb-IIIa were  qualitatively  similar,  con- 
siderably  more  Rap l b  was cytoskeleton associated than G P  
IIb-IIIa. After  10  min,  the  mole  ratio of Rap l b   t o   G P  IIb was 
approximately 200:l. PECAM-1, another integral membrane 
protein that becomes  associated  with the cytoskeleton during 
platelet  activation (331, was  also  incorporated  into  the  cytoskel- 
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FIG. 2. Rap lb incorporation  into  the  cytoskeleton  as  a  func- 
tion of calcium  and  aggregation  and  comparison  with  the  incor- 
poration of GP In-IIIa and PECAM-1. Platelets  were  activated  with 
thrombin (1 unit/ml)  at  time 0 in  the presence (0) and  absence (0) of 
calcium, then cytoskeletal  structures  were  isolated by lysis  in 1% Triton 
X-100 and  differential  centrifugation at the  indicated  times. Panel A, 
aggregation-dependent  association of Rap l b  with  the  cytoskeleton.  Rap 
l b  content of the cytoskeleton  was  measured by Western  blot  analysis 
as  described  under  "Materials  and Methods." Inset, Western  blot  anal- 
eton  in a biphasic  manner  that  was calcium and aggregation- 
dependent  with a time course that  was  qualitatively  similar to 
Rap lb  and  GP IIb-IIIa (Fig. 2,panel C ) .  The  parallels between 
the association of Rap l b  with  the cytoskeleton and  that of GP 
IIb-IIIa  and PECAM-1 raise  the  interesting possibility that  GP 
IIb-IIIa and/or PECAM-1 are associated with Rap l b  in the 
cytoskeleton. Torti et al. (34)  have  presented evidence  recently 
that  GP IIb-IIIa purified from resting  platelets  is associated 
with a 21-kDa GTP-binding protein,  but  the  identity of the 
protein was  unknown  and  platelets  contain  multiple GTP-bind- 
ing  proteins  in  this weight range  (14, 35). 
The association of Rap l b  with  the  activation-dependent cy- 
toskeleton was further compared with Rap-related proteins 
that  are  present  in  platelets,  including Ras-GAP and pp60'"". 
Ras-GAP is a single  chain protein containing a  carboxyl-termi- 
nal  catalytic  domain  and  an  amino-terminal domain that con- 
tains Src homology 2 (SH2) and 3 (SH3) regions (36). SH2 
regions have been  shown to bind  phosphorylated  tyrosine  resi- 
dues  in  proteins  and  mediate  the  interaction of GAP with  such 
tyrosine  kinase  substrates  in  platelets as Fyn, Lyn, Yes, and 
pp60""" (37,38).  Members of the  Rap family interact  with Ras- 
GAP to form a complex that competitively inhibits  the  interac- 
tion of Ras-GAP with  Ras  (39-41)  and  may  therefore  regulate 
signaling  through  the  Ras pathway. To see if Rap l b  was incor- 
porated  into  the cytoskeleton through  interactions  with Ras- 
GAP or pp60c-"rc,  we xamined the cytoskeleton  associations of 
these  proteins.  The  results  are  presented  in Figs. 3 and 4. As 
reported previously (42-44), pp60'"" is incorporated into  the 
detergent-extracted  activation-dependent cytoskeleton  (Fig. 3). 
However, in  contrast  to  Rap  lb,  the association with  the cy- 
toskeleton was  not calcium-dependent. Ras-GAP, on the  other 
hand,  was  not associated with  the cytoskeleton after cell acti- 
vation under conditions in which Rap l b  and pp60""" were 
associated with  the cytoskeleton  (Fig. 4). 
Several  platelet  substrates for CAMP-dependent protein ki- 
nase,  including  Rap l b  (211, GP  IbP  (45), actin-binding  protein 
(45,46),  and  vasodilator-stimulated phosphoprotein (47), asso- 
ciate  with  the  platelet cytoskeleton during cell activation. This 
tendency for substrates for CAMP-dependent protein kinase  to 
associate  with  the  activation-dependent cytoskeleton suggests 
that one possible mechanism by which phosphorylation of these 
proteins  might  mediate  platelet  inhibition by  CAMP is  through 
inhibition of their association with the cytoskeleton which 
might,  in  turn,  inhibit cytoskeletal  assembly or some  function 
of the cytoskeleton  needed for cell activation. To examine  this 
possibility, platelets were loaded with  [32Plorthophosphate then 
activated by adding 1 unitlml  thrombin  in  the presence of 1 PM 
PGI,. Higher  concentrations of PGI, were found to completely 
inhibit the activation  response and cytoskeleton  formation 
(data  not shown).  Five minutes  after  the  addition of thrombin, 
the cytoskeletons  were  isolated. A comparison of the radiopro- 
tein profile after activation of intact  platelets  treated  with pros- 
tacyclin (Fig. 5, lane 1 )  or control buffer  (Fig. 5, lane 3 )  shows 
that PGI, enhanced phosphorylation of Rap  lb. Phosphoryla- 
ysis of cytoskeletal  Rap l b  with  the monoclonal antibody M90 in  the 
absence (left  lane) and presence (right  lane) of calcium.  Molecular  mass 
standards are presented on the left.  Panel B,  GP  IIb incorporation  into 
the cytoskeleton. GP  IIb  content of the cytoskeleton  was  measured by 
Western blot analysis as described under "Materials and Methods." 
Inset, Western  blot  analysis of cytoskeletal  GP  IIb  with  the monoclonal 
antibody AP4 in  the  absence (left lane) and presence (right lane) of 
calcium.  Molecular mass  standards  are  presented on the left.  Panel C ,  
PECAM-1 incorporation  into  the  cytoskeleton.  PECAM-1  content of the 
"Materials  and  Methods." Inset, Western  blot  analysis of cytoskeletal 
cytoskeleton was  measured by Western  blot  analysis as  described  under 
PECA"1  with  the polyclonal antibody SEW-I6 in the absence (left 
lane) and  presence (right  lane) of calcium.  Molecular mass  standards 
are presented on the left. 
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FIG. 3. pp60c'" incorporation into the  cytoskeleton. Platelets 
were  activated at time 0 in  the presence (0) and  absence (0) of calcium 
with  thrombin (1 unitlml),  then  cytoskeletal  structures  were  isolated by 
Triton X-100 lysis and  differential  centrifugation at   the  indicated  times. 
pp6OC-'" content of the cytoskeleton  was  measured  with  Western  anal- 
y s ~ s   a s  described  under  "Materials  and Methods." Inset, Western  anal- 
ysis of cytoskeletal pp60"" with  the monoclonal antibody 327 in  the 
absence (left  lane) and  presence (right  lane) of calcium.  Molecular mass 
standards  are  presented  on  the  left. 
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FIG. 4. Localization of Ras-GAP upon  Triton X-100 fraction- 
ation. Platelets  were  activated  in  the  presence  ofcalcium  with  thrombin 
(1 unitlml) (+) or  control  buffer (-). After 5 min,  cytoskeletal  structures 
were  isolated  by  Triton X-100 lysis. Ras-GAP was  immunodetected  in 
low speed  cytoskeletal  pellet  after  activation  with  thrombin (lane 1) or 
control  buffer (lane 2 ) ,  high  speed  pellet  after  activation  with  thrombin 
(lane 3 )  or control  buffer (lane 4) ,  and  high  speed  supernatant  after 
activation with thrombin (lane 5) or control buffer (lane 6). Lane 7 
illustrates  immunodetection of intact  platelet  after 5 min of activation. 
The polyclonal antibody RH-6 was  used as described  under  "Materials 
and  Methods."  Molecular  mass  standards are presented on the left. 
tion  induces a 0.5-kDa increase  in  apparent molecular mass  (as 
reported previously (13)) to yield a closely spaced doublet of 
M90 antigens (Fig. 5, lane 2) ;  the upper and lower bands con- 
sisting of the phosphorylated and  unphosphorylated  forms of 
the protein,  respectively  (compare lanes 1 and 2 in Fig. 5). The 
autoradiogram of the  extracted cytoskeletons  (Fig. 5, lane 5), as 
well as  the M90 immunodetection  (Fig. 5, lane 6), show that  the 
phosphorylated as well as unphosphorylated  protein associated 
with  the  activated cytoskeleton. 
To ascertain if all isoforms of Rap l b  were  incorporated into 
the cytoskeleton, two-dimensional IEF SDS-PAGE was per- 
formed  (Fig. 6). Platelets were treated  with prostacyclin and 
activated for 5 min as described for Fig. 5. The  intact cell or 
isolated  cytoskeletons  were then subjected to two-dimensional 
electrophoresis and Western analysis  with M90. The isoform 
profile of M90 antigens  in  the cytoskeleton (Fig. 6, lower panel) 
was  similar  to  that of the  intact  platelet (Fig. 6, upper  panel 1. 
Both major phosphorylated isoforms, along with unphospho- 
rylated isoforms, were included in  the  structure  in approxi- 
mately  the  same proportion as contained in  the whole platelet. 
The  rates of incorporation of phosphorylated and unphospho- 
rylated  Rap l b  into  the cytoskeleton are  presented  in Fig. 7. 
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FIG. 5.  The inclusion of phosphorylated Rap lb in the  cytoskel- 
eton. Platelets  were  incubated  with  ["2Plorthophosphate,  exposed  to 1 
PM PGI, or control  buffer  for  10  minutes,  and  then  activated  with  throm- 
bin (1 unitlml)  in  the  presence of calcium.  Five  minutes  later,  cytoskel- 
eta1 structures  were  fractionated  with  Triton X-100 lysis  and  differen- 
tial  centrifugation. Lanes 1 and 2, platelets  after  PGI,  treatment  and 
activation. Lanes 3 and 4, platelets  after  activation  without PGI, treat- 
ment. Lanes 5 and 6, 10,000 x g cytoskeletal  pellet from platelets  acti- 
vated  after PGI, treatment. Lanes 7 and 8,10,000 x g  cytoskeletal  pellet 
from  platelets  activated  without PGI, exposure. Lanes 1, 3, 5 ,  and 7, 
autoradiograms. Lanes 2 ,4 ,6 ,  and 8, Rap l b  indirect  immunostain  with 
M90. Solid and open  arrows indicate  the  position of phosphorylated  and 
unphosphorylated  Rap lb,  respectively. 
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FIG. 6. The inclusion of Rap lb isoforms in the  platelet cy- 
toskeletons. Platelets were incubated with 1"2Plorthophosphate, ex- 
posed to 1 p~ PGI, for 10 min,  and  then  activated  with  thrombin (1 
unitlml) in the presence of calcium. Five minutes later, cytoskeletal 
structures  were  fractionated  with  Triton X-100 lysis and  differential 
centrifugation.  The  platelet  and  cytoskeletal  proteins  were  subjected  to 
IEF SDS-PAGE and then Western analysis with M90. Solid arrows 
indicate  the  two  major  phosphorylated  isoforms of Rap  lb.  Molecular 
mass  and isoelectric standards are on the left and bottom, respectively. 
Platelets were loaded with [32P]orthophosphate, treated  with 
prostacyclin, and  then  activated as in  the  experiments  in Figs. 
5 and 6. The phosphorylation-induced change  in electrophoretic 
mobility of Rap l b  was  used  to  measure  the  content of phos- 
phorylated and  unphosphorylated  Ras protein in  the cytoskel- 
eton. Both the  phosphorylated  and  unphosphorylated forms of 
Rap l b  associated with  the cytoskeleton with  similar  rates. 
These  results  make  it  unlikely  the phosphorylation inhibits 
platelets by inhibiting association of Rap l b  with  the cytoskel- 
eton. The phosphorylated form of Rap l b  was associated with 
the  activation-dependent cytoskeleton and  the  rate of associa- 
tion of the phosphorylated Rap l b  with  the cytoskeleton was  the 
same as that of the  unphosphorylated  Rap  lb. Fox et al. (45) 
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FIG. 7. Incorporation of phosphorylated and unphosphoryl- 
ated Rap lb in the cytoskeleton. Platelets were incubated with 
[3zPJorthophosphate, exposed to 1 p~ PGI, or control  buffer  for 15 min, 
and then activated with thrombin (1 uniffml) in  the presence of calcium. 
At the indicated times, cytoskeletal structures were fractionated with 
Triton X-100 lysis and differential centrifugation. Phosphorylated (0) 
measured with SDS-PAGE and Western analysis with M90 as described 
and unphosphorylated (0) Rap l b  content of the cytoskeleton were 
under “Materials and Methods.” 
have also observed that  the phosphorylated forms of GP Ibp and 
actin-binding protein were able to  associate with the cytoskel- 
eton. Phosphorylation of Rap l b  might have other effects that 
could inhibit platelets. Phosphorylation might affect  some  fimc- 
tion of the proteins after  their association with the cytoskeleton. 
This would predict that  the association of phosphorylated and 
unphosphorylated Rap l b  with the cytoskeleton  would be in- 
distinguishable but events  after the association of the phospho- 
rylated protein would  be impaired. Phosphorylation might also 
affect the cellular distribution of the proteins in  the resting cell, 
and  this might affect their function in  the cytoskeleton after 
activation. Lapetina et al. (13) have presented evidence indi- 
cating that Rap l b  is dissociated from the plasma membrane 
upon phosphorylation by  CAMP-dependent protein kinase. This 
suggests a model in which unphosphorylated Rap lb, integrated 
in  the plasma membrane, may form a  site of attachment for the 
cytoskeleton, perhaps providing direction for the contractile 
mechanism, or may mediate the incorporation of some  mem- 
brane protein into the cytoskeleton. The parallels between the 
association of Rap l b  with the cytoskeleton and that of GP IIb- 
IIIa are interesting  in this regard. Upon phosphorylation, Rap 
l b  dissociates from the membrane. The dissociated Rap l b  
might be incorporated into the cytoskeleton upon  cell activation 
but would  be incapable of forming an attachment  site or escort- 
ing membrane proteins into the cytoskeleton. Better under- 
standing of the role of Rap l b  in  the cytoskeleton is needed to 
distinguish between these possibilities. 
In summary, we show that Rap l b  incorporation into the 
cytoskeleton is  a specific event which is maximal with thrombin 
activation in  the presence of extracellular calcium and/or cell 
aggregation. The initial rate of Rap l b  association with the 
cytoskeleton is  rapid, occurring within seconds, and  is  paral- 
leled by the association with the cytoskeleton of integral mem- 
brane proteins like GP IIb-IIIa  and PECA”1. Although the 
role of Rap lb  in  the cytoskeleton remains  uncertain, the rapid 
initial association means that Rap l b  could participate  in both 
the initial formation of the cytoskeleton as well as longer term 
reorganizations that occur in  the cytoskeleton. Whether or not 
there  is association within the cytoskeleton between Rap l b  
and GP IIb-IIIa and/or PECAM-1 remains to be determined. 
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